Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to determine if tumor cells can be detected in the blood of patients diagnosed with a brain tumor.
Despite aggressive therapies, Glioblastoma Multiforme (GBM) is rapidly fatal. GBMs are increasingly recognized for occasionally metastasizing through the peripheral blood to distant locations. This research study involves the detection and novel characterization of human GBM (hGBM) circulating tumor cells (CTCs) within the peripheral blood of brain tumor patients by identifying their unique cell surface antigen profile, determining an optimal isolation protocol, and quantitatively and qualitatively reporting the yield and characteristics.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| GBM Patients | GBM Patients with a histologically confirmed or suspected diagnosis of glioblastoma multiforme. |
| |
| Normal Controls | Normal Controls will be adult volunteers who identify themselves as not having been diagnosed with a glioblastoma multiforme. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| GBM Patients | Other | 2 teaspoons of blood will be collected during select clinic visits. |
| |
| Measure | Description | Time Frame |
|---|---|---|
| Identification of Human GBM CD Antigen Signature. | Already established and stored GBM cell lines will be screened for CD antigens to confirm that a selective cell surface antigen can be identified. | 3 Years |
| Measure | Description | Time Frame |
|---|---|---|
| Identification & Isolation of Human GBM Cells in Seeded Normal Control Human Blood. | Frozen and fresh human blood will be seeded with human GBM cells from established stored GBM cell lines and subjected to antibody-based cell identification and isolation procedures. | 3 Years |
| Prospective Isolation of GBM Tumor Cells in GBM Patient Blood. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Participants will be recruited during routine interactions with the investigators.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Brent Reynolds, PhD | University of Florida | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| University of Florida | Gainesville | Florida | 32610 | United States |
Not provided
| ID | Term |
|---|---|
| D005909 | Glioblastoma |
| D001932 | Brain Neoplasms |
| ID | Term |
|---|---|
| D001254 | Astrocytoma |
| D005910 | Glioma |
| D018302 | Neoplasms, Neuroepithelial |
| D017599 | Neuroectodermal Tumors |
Not provided
Not provided
Not provided
Not provided
Not provided
| Normal Controls |
| Other |
2 teaspoons of blood will be collected once. |
|
Circulating tumor cells will be isolated from blood drawn from GBM patients. |
| 3 Years |
| Prospective Evaluation of the Routine Medical History of GBM Patients. | Medical records of GBM patients will be used to determine how circulating tumor cells impact outcome. | 3 Years |
| D009373 |
| Neoplasms, Germ Cell and Embryonal |
| D009370 | Neoplasms by Histologic Type |
| D009369 | Neoplasms |
| D009375 | Neoplasms, Glandular and Epithelial |
| D009380 | Neoplasms, Nerve Tissue |
| D016543 | Central Nervous System Neoplasms |
| D009423 | Nervous System Neoplasms |
| D009371 | Neoplasms by Site |
| D001927 | Brain Diseases |
| D002493 | Central Nervous System Diseases |
| D009422 | Nervous System Diseases |